CREARE LLC SBIR Phase II Award,

Cognitive decline is a major quality of life concern for many cancer survivorsThevarious available treatments affect individuals differentlyand research has unfortunately provided little guidance on how specific treatments impact neurocognitive functionTo help researchers fill this information gap and ultimately provide guidance to doctors and patientsa neuropsychological assessment system that is designed specifically for repeated assessment of cancer patients and survivors is needed Creare will develop the Neuropsychological Assessment System for Cancer Patients NASCPa mobileself administeredrepeatable neuropsychological assessment system specific to cancer patients and survivors comprising of a mobile appa secure HIPAA compliant serverand a web portal for researchers and cliniciansThe components of the NASCP will be assessed in a human study